| Range: | 1.41-89.11 | Vol Avg: | 579245 | Last Div: | 0 | Changes: | 6.64 |
| Beta: | 2.18 | Cap: | 2.16B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Nov 04 2020 | Empoloyees: | 1000 | ||
| CUSIP: | 81663L200 | CIK: | 0001818331 | ISIN: | US81663L2007 | Country: | US |
| CEO: | Ms. Katherine A. Stueland | Website: | https://www.genedx.com | ||||
WGS 78.74 Stock Price GeneDx Holdings Corp.
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Stock Details
Neutral 0.00
GeneDx to Participate in Upcoming Investor Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company manage...
businesswire.com·Fri Nov 22 2024
Positive 0.26
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved he...
businesswire.com·Mon Nov 18 2024
Neutral 0.06
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past yea...
seekingalpha.com·Wed Oct 30 2024
Positive 0.27
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30...
seekingalpha.com·Tue Oct 29 2024
Neutral 0.00
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its f...
businesswire.com·Tue Oct 29 2024
Positive 0.35
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise ...
seekingalpha.com·Mon Oct 21 2024
Neutral 0.00
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results...
businesswire.com·Thu Oct 03 2024
Neutral -0.10
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensati...
businesswire.com·Fri Sep 27 2024
Positive 0.20
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. ...
investors.com·Thu Sep 19 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow